These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 29370683)
21. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276 [TBL] [Abstract][Full Text] [Related]
22. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab. Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860 [TBL] [Abstract][Full Text] [Related]
24. Smoking is not associated with higher prevalence of JC virus in MS patients. Auer M; Bsteh G; Hegen H; Di Pauli F; Wurth S; Berger T; Deisenhammer F Eur J Clin Microbiol Infect Dis; 2018 May; 37(5):907-910. PubMed ID: 29423619 [TBL] [Abstract][Full Text] [Related]
25. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. Bagherieh S; Afshari-Safavi A; Vaheb S; Kiani M; Ghaffary EM; Barzegar M; Shaygannejad V; Zabeti A; Mirmosayyeb O Neurol Sci; 2023 Jun; 44(6):1905-1915. PubMed ID: 36745300 [TBL] [Abstract][Full Text] [Related]
26. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481 [TBL] [Abstract][Full Text] [Related]
27. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time. Peters J; Williamson E J Neurol; 2017 Dec; 264(12):2409-2412. PubMed ID: 29034436 [TBL] [Abstract][Full Text] [Related]
28. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. Outteryck O; Ongagna JC; Duhamel A; Zéphir H; Collongues N; Lacour A; Fleury MC; Berteloot AS; Blanc F; Giroux M; Vermersch P; de Sèze J J Neurol; 2012 Nov; 259(11):2293-8. PubMed ID: 22527227 [TBL] [Abstract][Full Text] [Related]
29. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722 [TBL] [Abstract][Full Text] [Related]
31. Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence. Koolaji S; Allahabadi NS; Ahmadi A; Eskandarieh S; Moghadasi AN; Azimi AR; Sahraian MA J Neurovirol; 2018 Oct; 24(5):570-576. PubMed ID: 29785581 [TBL] [Abstract][Full Text] [Related]
32. Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study. Auer M; Hegen H; Sellner J; Oppermann K; Bsteh G; Di Pauli F; Berger T; Deisenhammer F Brain Behav; 2019 Jul; 9(7):e01332. PubMed ID: 31168964 [TBL] [Abstract][Full Text] [Related]
33. JCV serology in time: 3 years of follow-up. Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611 [TBL] [Abstract][Full Text] [Related]
34. A longitudinal study of JC virus serostatus stability among multiple sclerosis patients. Alroughani R; Akhtar S; Ahmed S; Al-Hashel J Mult Scler Relat Disord; 2018 Feb; 20():132-135. PubMed ID: 29414286 [TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus persistence and reactivation in neuromyelitis optica. Masuda S; Mori M; Arai K; Uzawa A; Muto M; Uchida T; Masuda H; Kuwabara S J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1137-42. PubMed ID: 25433035 [TBL] [Abstract][Full Text] [Related]
36. Age-Dependent Seroprevalence of JCV Antibody in Children. Hennes EM; Kornek B; Huppke P; Reindl M; Rostasy K; Berger T Neuropediatrics; 2016 Apr; 47(2):112-4. PubMed ID: 26479766 [TBL] [Abstract][Full Text] [Related]
37. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study. Hegen H; Auer M; Bsteh G; Di Pauli F; Plavina T; Walde J; Deisenhammer F; Berger T PLoS One; 2017; 12(3):e0174005. PubMed ID: 28319193 [TBL] [Abstract][Full Text] [Related]
38. Correlation between anti-JC-virus and anti-cytomegalovirus, -Epstein-Barr virus and -measles/-rubella/-varicella-zoster-virus antibodies. Auer M; Borena W; Holm-von Laer D; Deisenhammer F J Med Virol; 2017 Jan; 89(1):3-9. PubMed ID: 27253624 [TBL] [Abstract][Full Text] [Related]
39. Anti-JC virus antibodies: implications for PML risk stratification. Gorelik L; Lerner M; Bixler S; Crossman M; Schlain B; Simon K; Pace A; Cheung A; Chen LL; Berman M; Zein F; Wilson E; Yednock T; Sandrock A; Goelz SE; Subramanyam M Ann Neurol; 2010 Sep; 68(3):295-303. PubMed ID: 20737510 [TBL] [Abstract][Full Text] [Related]
40. Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. Aoyama S; Mori M; Uzawa A; Uchida T; Masuda H; Ohtani R; Kuwabara S Mult Scler; 2020 Jan; 26(1):128-129. PubMed ID: 30362874 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]